91P Immune-mediated Adverse Event (imae) Incidence, Timing and Association with Efficacy in the Phase III TOPAZ-1 Study of Durvalumab (D) or Placebo (PBO) Plus Gemcitabine and Cisplatin (+ GC) in Advanced Biliary Tract Cancer (BTC)

L. Antonuzzo,H. Takahashi,J.O. Park,A. Sookprasert,R. Gillmore,S-S. Yang,J.E. Cundom,M. Petrova,G.M. Vaccaro,M. Holmblad,J. Xiong,K. Heider,N. Rokutanda,D-Y. Oh

Annals of oncology（2022）

引用 0|浏览2

暂无评分

摘要

In TOPAZ-1 (NCT03875235), D + GC significantly improved overall survival (OS) vs PBO + GC for patients (pts) with advanced BTC (Oh et al. NEJM Evid 2022; https://doi.org/10.1056/EVIDoa2200015). D (immune checkpoint inhibitor) may cause imAEs; imAEs have been associated with improved OS (Zhou et al. BMC Med 2020;18:87).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要